^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ATA3271

    i
    Other names: ATA3271, allogeneic CAR T immunotherapy targeting mesothelin , allogeneic MSLN CAR+ EBV T cells
    Company:
    Atara
    Drug class:
    Mesothelin-targeted CAR-T immunotherapy
    Related drugs:
    over2years
    BAY1688/ATA3271: An Armored, Next-Generation, Off-the-Shelf Mesothelin-CAR T Cell Therapy for Solid Tumors (ASGCT 2022)
    Conclusions These studies reveal potent anti-tumor activity, both in vitro and in vivo, of BAY1688/ATA3271 allogeneic CAR-T cells generated using an original and an optimized manufacturing process. Overall, BAY1688/ATA3271 may be a promising approach for the treatment of MSLN-positive malignancies, and this data warrants further development of this program towards clinical trials.
    CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD19 (CD19 Molecule) • MSLN (Mesothelin) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • GZMB (Granzyme B)
    |
    PD-L1 expression • MSLN expression • MSLN positive • PD-L1-H
    |
    ATA3271
    3years
    ATA3271: An Armored, Next-Generation Off-The-Shelf, Allogeneic, Mesothelin-CAR T Cell Therapy for Solid Tumors (SITC 2021)
    Memory marker expression impact on ATA3271 potency, both in vitro and in vivo, will be presented. Conclusions Overall, these in vitro and in vivo data show potent anti-tumor activity without evidence of toxicity, suggesting that ATA3271 may be a promising approach for the treatment of MSLN-positive cancers that warrants further clinical investigation.
    CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD19 (CD19 Molecule) • MSLN (Mesothelin) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • CCR7 (Chemokine (C-C motif) receptor 7) • GZMB (Granzyme B)
    |
    PD-L1 expression • MSLN expression • MSLN positive
    |
    ATA3271
    4years
    [VIRTUAL] ATA3271: An Armored, Next-Generation Off-The-Shelf, Allogeneic, Mesothelin-CAR T Cell Therapy for Solid Tumors (SITC 2020)
    Additionally, ATA3271 retains endogenous EBV TCR function and reduced allotoxicity in the context of HLA mismatched targets. Conclusions Overall, ATA3271 shows potent anti-tumor activity without evidence of allotoxicity, both in vitro and in vivo, suggesting that allogeneic MSLN-CAR-engineered EBV T cells are a promising approach for the treatment of MSLN-positive cancers and warrant further clinical investigation.
    CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD19 (CD19 Molecule) • MSLN (Mesothelin)
    |
    PD-L1 expression • PD-L1 overexpression • PD-1 expression • PD-L1-H
    |
    ATA3271
    4years
    [VIRTUAL] ATA3271: An Armored, Next-Generation Off-The-Shelf, Allogeneic, Mesothelin-CAR T Cell Therapy for Solid Tumors (SITC 2020)
    Additionally, ATA3271 retains endogenous EBV TCR function and reduced allotoxicity in the context of HLA mismatched targets. Conclusions Overall, ATA3271 shows potent anti-tumor activity without evidence of allotoxicity, both in vitro and in vivo, suggesting that allogeneic MSLN-CAR-engineered EBV T cells are a promising approach for the treatment of MSLN-positive cancers and warrant further clinical investigation.
    CAR T-Cell Therapy • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD19 (CD19 Molecule) • MSLN (Mesothelin)
    |
    PD-L1 expression • PD-L1 overexpression • PD-1 expression • PD-L1-H
    |
    ATA3271